Press

2021-12-06

Kancera appoints Peter Selin as Executive Vice President Corporate Development

Kancera AB (publ) today announces that Peter Selin has been appointed as Executive Vice President Corporate Development, responsible for business development, strategic partnerships and licensings. He will be part of the management team and report directly to the CEO.

Read More
2021-05-21

Interim report for first quarter 2021, 1 January – 31 March 2021

First quarter in brief Net sales for the period (January to March) amounted to SEK 0 million (SEK 0 million). R&D costs for the period amounted to SEK 8,2 million (SEK 9,7 million). Operating profit for the period amounted...

Read More
2021-04-21

Kancera provides an update on the development of the company’s pharmaceutical project and nominates a new drug candidate

two thirds of patients have now been dosed in the clinical study of KAND567 for the treatment of COVID-19; patient recruitment is expected to be completed during the current quarter, successful scaling up of production of the drug candidate...

Read More
2020-08-21

Interim report for the second quarter 2020. January 1st – June 30th, 2020

Second quarter in brief and the period 1 January – 30 June 2020   Net sales for the period (January to June) amounted to SEK 2,6 million (3,1 million), of which the second quarter contributed SEK 2,6 million (0)....

Read More
2019-08-23

Interim report for the second quarter 2019, 1 January – 30 June 2019

Second quarter in brief 1 April – 30 June 2019 Net sales for the period (January to June) amounted to SEK 3,1 Million (0 Million) of which the second quarter contributed SEK 0 Million (0 Million). R&D costs for...

Read More
2019-05-24

INTERIM REPORT FOR THE FIRST QUARTER 2019, 1 January – 31 March 2019

First quarter in brief 1 January – 31 March 2019 Net sales for the period (January to March) amounted to SEK 0.0 million (SEK 0.0 million) R&D costs for the period amounted to SEK 10,2 million (SEK 11,8 million)....

Read More
2018-11-23

INTERIM REPORT FOR KANCERA  AB (publ) 1st January – 30th September 2018

PERIOD JAN – SEPTEMBER 2018, AND THIRD QUARTER IN BRIEF • Net sales for the period (January to September) amounted to SEK 0.1 million (SEK 0.1 million) of which the third quarter amounted to SEK 0.1 million (SEK 0.0 million). • R&D...

Read More
2018-04-27

Time plan for Kancera’s rights issue

Today, Friday, April 27, 2018 is the last day of trading in Kancera's share, including the right to participate in the rights issue. Otherwise, the following time plan applies (dates refer to 2018):  Friday April 27th: Last day for trading...

Read More
2018-02-20

YEAR END REPORT KANCERA  AB (publ) 1st January – 31st December 2017

PERIOD 1 JAN – 31 DEC 2017 IN BRIEF • Net turnover for the period amounted to SEK 0.1 million (0.3 million). For the fourth quarter, turnover amounted to 0.0 MEK (0.1 M). • R & D expenses for the period amounted to...

Read More
2017-11-21

Kancera performs the second partial payment for the Fractalkine project

According to the agreement with Acturum Real Estate AB, the second partial payment for the Fractalkine project is due when the drug candidate KAND567 has been given to a certain number of subjects in the ongoing Phase Ia study.Therefore,...

Read More